Introduction
The publication of environmental risk assessment summaries is part of Roche's engagement on developing a better understanding of issues regarding pharmaceuticals in the environment (PIE).
New pharmaceutical substances are investigated for biodegradability and initial ecotoxicity during their development. For registration, a full state-of-the-art environmental risk assessment is developed based on chronic environmental effects and advanced environmental fate data, as required by the pertinent regulations. While not a regulatory requirement, Roche also investigates older pharmaceutical substances, normally at a simpler scale, in order to assess their environmental risks.
For active pharmaceutical ingredients, the potential environmental risk is calculated from the ratio between the Predicted Environmental Concentration (PEC) of the substance in the aquatic environment based on a conservative emission scenario and the Predicted No Effect Concentration (PNEC), a concentration below which no adverse effects on the environment have to be expected.
Summary
Vismodegib is used to treat adults with a type of skin cancer, called basal cell carcinoma that has spread to other parts of the body or cannot be treated effectively with surgery or radiation. Vismodegib works by blocking abnormal functioning of the Hedgehog cell signalling pathway. Abnormal activation of this pathway is responsible for tumour development in most basal cell carcinomas [7] .
Vismodegib is the active pharmaceutical ingredient used in the Roche product Erivedge.
Major metabolic pathways of Vismodegib involve primary oxidations followed by sequential glucuronidation or sulfation. Orally administered Vismodegib is absorbed and slowly eliminated by a combination of metabolism and excretion of parent drug, the majority of which is recovered in the faeces (82% of the administered dose), with 4.4% of the administered dose recovered in urine [7] .
Vismodegib is not readily biodegradable in standard OECD tests over 28 days. In water/sediment systems over 100 days, only partial transformation of Vismodegib was observed. No significant mineralisation (formation of CO2) was observed.
The PEC/PNEC ratio is 0.00004. With reference to the Guideline on the Environmental Risk Assessment on Medicinal Products for Human Use of the European Medicines Agency [6] , a PEC/PNEC ratio of ≤1 means that Vismodegib and/or its metabolites are unlikely to represent a risk to the aquatic environment. 
Note:
Vismodegib is at least partially metabolised in the body. Since little is known about the ecotoxicity of these metabolites, it is assumed as a worst case that they have the same ecotoxicological relevance as Vismodegib.
Predicted No Effect Concentration (PNEC)
Chronic studies have been performed for species from three trophic levels, based on OECD Test 
